BMTCN REVIEW EXAMS ALL QUESTIONS AND
ANSWERS SURE A+
✔✔match unrelated - ✔✔hla identical unrelated donor
a: no potential stem cell contamination
d: increased risk of gvhd, limited numbers of non caucasian donors, waiting period to
identify donor
✔✔mismatch unrelated - ✔✔hla non identical unrelated donor
a: no potential stem cell contamination
d: increased risk of gvhd, high treatment related mortality
✔✔umbilical cord blood - ✔✔umbilical cord unit
a: easy access to cell source
d: a limited number of cells, delayed time to engraftment, increase infection rates.
✔✔goals of therapy non malignant diseases - ✔✔cell line replacement (chronic
granulomatous disease, sickle cell disease, aplastic anemia)
✔✔goal of therapy for malignant diseases - ✔✔tumor ablation
✔✔graft versus tumor effect - ✔✔promoted by the withdrawal of immunosuppressant
therapy
promoted by donor lymphocyte infusions
decreased in the absence of acute GVHD
associated with a higher rate of cancer relapse
✔✔immune reconstitution depends on - ✔✔patient hematologic response to preparative
treatment
rate of engraftment
survival and longevity of mature lymphocytes present at the time of the transplant
delays on pt with chronic GVHD
,quantitative recovery of immune functions does not always correlate with qualitative
recovery
immune reconstitution may take months to years
✔✔phases of immune reconstitution - ✔✔numeric recovery of bone marrow elements
functional recovery of cellular interactions
✔✔indications for transplantation autoimmune diseases - ✔✔scleroderma
ms
systemic lupus erythematosus
rheumatoid arthritis
chron disease
✔✔autologous transplant (hematologic malignant) - ✔✔Hodgkin disease
non-Hodgkin lymphoma
multiple myeloma
✔✔autologous transplant (solid tumors malignant) - ✔✔neuroblastoma
sarcoma
germ cell tumors
brain tumors
breast cancer
ovarian cancer
melanoma
lung cancer
✔✔allogeneic transplant (malignant) - ✔✔acute lymphocytic leukemia
acute myeloid leukemia
chronic myeloid leukemia
myelodysplastic syndromes
non-hodgkin lymphoma
juvenile myelomonocytic leukemia
✔✔allogeneic transplant non malignant - ✔✔severe aplastic anemia
Fanconi anemia
thalassemia
sickle cell disease
diamond blackfan anemia
cheduak-higashi syndrome
chronic granulomatous disease
congenital neutropenia
✔✔immunodeficiency non malignant allogeneic - ✔✔severe combined
immunodeficiency disease
wiskott-Aldrich syndrome
,functional t cell deficiency
✔✔genetic non malignant allogeneic - ✔✔adrenoleukodystrophy
metachromatic leukodystrophy
hurler syndrome
hunter syndrome
gaucher sundrome
✔✔allogeneic non malignant - ✔✔osteopetrosis
Langerhans cell histiocytosis
glycogen storage diseases
✔✔example of myeloid cell - ✔✔monocytes
✔✔Hematopoiesis occurs primary in - ✔✔bone marrow
✔✔graft versus tumor effect is promoted by - ✔✔withdrawal of immunosuppressive
therapy and administration of donor lymphocytes infusion
✔✔stem cells can be collected and kept in a facility that is accredited - ✔✔by the FACT
foundation for the accreditation of cellular therapy
✔✔advantage of autologus tansplant - ✔✔easily available source of stem cells
decreased risk of side effects
early engraftment
low risk of graft versus host disease (gvhd)
✔✔the testing for allorgeneic - ✔✔is done to determine the strength of match through
human leukocytes antigen (hla) antigen
✔✔the higher the degree of mismatch - ✔✔the greater the like hood that the recipient
will develop life threatening complications such as GVHD
✔✔haploidentical - ✔✔half-matched related
✔✔advantage for allogeneic transplant - ✔✔disease-free stem cell source
potential for gvt effect
✔✔synegeneic - ✔✔hsct use the stem cells of an identical twin ( same hla tping)
✔✔DLI donor lyphocyte infusion - ✔✔infusion of lymphocytes from the original donor
given the setting of relapsed disease after allogeneic transplant. this is for the immune
system to fight the tumor inducing a gvt effect.
, ✔✔eligibility criteria for hsct - ✔✔comorbidities
stage of cancer
performance status
donor availability
✔✔first criterion to determine eligibility - ✔✔if pt's disease is chemotherapy-sensitive
(more concern with autologous )
acceptable organ function and is free of life-threatening viral exposures or diseases
pt compliance with regimen as well as support system
✔✔chemistry panel - ✔✔electrolytes
liver and kidney function test
✔✔multiple infectious diseases - ✔✔hep B,C
HIV
Human T-cell leukemia virus type 1
cytomegalovirus
herpes simplex virus and varicella zoster virus
✔✔health literacy - ✔✔the degree to which an individual has the capacity of obtain,
communicate, process and understand basic health information and services to make
appropriate health decision.
✔✔disease evaluation - ✔✔bm aspirate and biopsy
lumbar puncture
ct and MRI
bone scan as well 24 urine electrophoresis, quantitative immunoglobin test, and urine
catecholamines
✔✔HLA - ✔✔is a glycoprotein that resides on the surgace of cells located on
chromosome 6 and play major role in the immune system's ability to recognized self
versus nonself.
✔✔hla major action is to - ✔✔produce immune cells that destroy antigens
✔✔abo compability is not imperative because - ✔✔bone marrow collected rbc can be
filtered out to prevent rbc lysis after bone marrow infusion
after transplant the recipient will seroconvert to the donor blood type.
✔✔ideal donor - ✔✔young male with heavier weight (male)
if female younger and heavier size and no prior pregnancies
✔✔african american factors that influence becming a donor - ✔✔mistrust in the
american system
concerns about donors expenses
ANSWERS SURE A+
✔✔match unrelated - ✔✔hla identical unrelated donor
a: no potential stem cell contamination
d: increased risk of gvhd, limited numbers of non caucasian donors, waiting period to
identify donor
✔✔mismatch unrelated - ✔✔hla non identical unrelated donor
a: no potential stem cell contamination
d: increased risk of gvhd, high treatment related mortality
✔✔umbilical cord blood - ✔✔umbilical cord unit
a: easy access to cell source
d: a limited number of cells, delayed time to engraftment, increase infection rates.
✔✔goals of therapy non malignant diseases - ✔✔cell line replacement (chronic
granulomatous disease, sickle cell disease, aplastic anemia)
✔✔goal of therapy for malignant diseases - ✔✔tumor ablation
✔✔graft versus tumor effect - ✔✔promoted by the withdrawal of immunosuppressant
therapy
promoted by donor lymphocyte infusions
decreased in the absence of acute GVHD
associated with a higher rate of cancer relapse
✔✔immune reconstitution depends on - ✔✔patient hematologic response to preparative
treatment
rate of engraftment
survival and longevity of mature lymphocytes present at the time of the transplant
delays on pt with chronic GVHD
,quantitative recovery of immune functions does not always correlate with qualitative
recovery
immune reconstitution may take months to years
✔✔phases of immune reconstitution - ✔✔numeric recovery of bone marrow elements
functional recovery of cellular interactions
✔✔indications for transplantation autoimmune diseases - ✔✔scleroderma
ms
systemic lupus erythematosus
rheumatoid arthritis
chron disease
✔✔autologous transplant (hematologic malignant) - ✔✔Hodgkin disease
non-Hodgkin lymphoma
multiple myeloma
✔✔autologous transplant (solid tumors malignant) - ✔✔neuroblastoma
sarcoma
germ cell tumors
brain tumors
breast cancer
ovarian cancer
melanoma
lung cancer
✔✔allogeneic transplant (malignant) - ✔✔acute lymphocytic leukemia
acute myeloid leukemia
chronic myeloid leukemia
myelodysplastic syndromes
non-hodgkin lymphoma
juvenile myelomonocytic leukemia
✔✔allogeneic transplant non malignant - ✔✔severe aplastic anemia
Fanconi anemia
thalassemia
sickle cell disease
diamond blackfan anemia
cheduak-higashi syndrome
chronic granulomatous disease
congenital neutropenia
✔✔immunodeficiency non malignant allogeneic - ✔✔severe combined
immunodeficiency disease
wiskott-Aldrich syndrome
,functional t cell deficiency
✔✔genetic non malignant allogeneic - ✔✔adrenoleukodystrophy
metachromatic leukodystrophy
hurler syndrome
hunter syndrome
gaucher sundrome
✔✔allogeneic non malignant - ✔✔osteopetrosis
Langerhans cell histiocytosis
glycogen storage diseases
✔✔example of myeloid cell - ✔✔monocytes
✔✔Hematopoiesis occurs primary in - ✔✔bone marrow
✔✔graft versus tumor effect is promoted by - ✔✔withdrawal of immunosuppressive
therapy and administration of donor lymphocytes infusion
✔✔stem cells can be collected and kept in a facility that is accredited - ✔✔by the FACT
foundation for the accreditation of cellular therapy
✔✔advantage of autologus tansplant - ✔✔easily available source of stem cells
decreased risk of side effects
early engraftment
low risk of graft versus host disease (gvhd)
✔✔the testing for allorgeneic - ✔✔is done to determine the strength of match through
human leukocytes antigen (hla) antigen
✔✔the higher the degree of mismatch - ✔✔the greater the like hood that the recipient
will develop life threatening complications such as GVHD
✔✔haploidentical - ✔✔half-matched related
✔✔advantage for allogeneic transplant - ✔✔disease-free stem cell source
potential for gvt effect
✔✔synegeneic - ✔✔hsct use the stem cells of an identical twin ( same hla tping)
✔✔DLI donor lyphocyte infusion - ✔✔infusion of lymphocytes from the original donor
given the setting of relapsed disease after allogeneic transplant. this is for the immune
system to fight the tumor inducing a gvt effect.
, ✔✔eligibility criteria for hsct - ✔✔comorbidities
stage of cancer
performance status
donor availability
✔✔first criterion to determine eligibility - ✔✔if pt's disease is chemotherapy-sensitive
(more concern with autologous )
acceptable organ function and is free of life-threatening viral exposures or diseases
pt compliance with regimen as well as support system
✔✔chemistry panel - ✔✔electrolytes
liver and kidney function test
✔✔multiple infectious diseases - ✔✔hep B,C
HIV
Human T-cell leukemia virus type 1
cytomegalovirus
herpes simplex virus and varicella zoster virus
✔✔health literacy - ✔✔the degree to which an individual has the capacity of obtain,
communicate, process and understand basic health information and services to make
appropriate health decision.
✔✔disease evaluation - ✔✔bm aspirate and biopsy
lumbar puncture
ct and MRI
bone scan as well 24 urine electrophoresis, quantitative immunoglobin test, and urine
catecholamines
✔✔HLA - ✔✔is a glycoprotein that resides on the surgace of cells located on
chromosome 6 and play major role in the immune system's ability to recognized self
versus nonself.
✔✔hla major action is to - ✔✔produce immune cells that destroy antigens
✔✔abo compability is not imperative because - ✔✔bone marrow collected rbc can be
filtered out to prevent rbc lysis after bone marrow infusion
after transplant the recipient will seroconvert to the donor blood type.
✔✔ideal donor - ✔✔young male with heavier weight (male)
if female younger and heavier size and no prior pregnancies
✔✔african american factors that influence becming a donor - ✔✔mistrust in the
american system
concerns about donors expenses
